We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Lancet Oncol 2021 Oct 14;[EPub Ahead of Print], JJ Gao, J Cheng, TM Prowell, E Bloomquist, S Tang, SB Wedam, M Royce, D Krol, C Osgood, G Ison, R Sridhara, R Pazdur, JA Beaver, L Amiri-Kordestani